Shanghai Fosun Pharmaceutical Group Co Ltd (2196.HK)
Company Info
Highlights
HK$60.99B
HK$0.83
11.68
1.00
HK$40.33B
HK$19.12B
HK$1.58B
HK$11.52 - HK$19.50
HK$16.65
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
Loading data...
Returns By Period
Shanghai Fosun Pharmaceutical Group Co Ltd (2196.HK) returned -2.27% year-to-date (YTD) and 5.56% over the past 12 months. Over the past 10 years, 2196.HK returned -5.93% annually, underperforming the S&P 500 benchmark at 10.46%.
2196.HK
-2.27%
1.17%
-11.10%
5.56%
-11.61%
-5.93%
^GSPC (Benchmark)
-3.77%
7.44%
-5.60%
8.37%
14.12%
10.46%
Monthly Returns
The table below presents the monthly returns of 2196.HK, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | -6.95% | 16.01% | -1.71% | -6.55% | -1.43% | -2.27% | |||||||
| 2024 | -22.00% | 6.79% | -9.60% | -3.75% | -0.65% | 8.01% | 0.48% | -4.01% | 25.04% | -5.01% | -3.24% | -1.54% | -15.12% |
| 2023 | 0.80% | -8.93% | -2.83% | 0.22% | -4.70% | -1.88% | 0.29% | -9.95% | -0.32% | -1.96% | -4.21% | -1.62% | -30.47% |
| 2022 | -9.17% | 0.32% | 22.36% | -11.49% | -2.51% | -10.26% | -2.24% | -10.74% | -24.89% | 4.10% | 30.17% | -3.10% | -25.70% |
| 2021 | -5.53% | 4.57% | -9.43% | 48.87% | 31.00% | -3.02% | 14.44% | -29.82% | -19.74% | -8.36% | 9.95% | -14.87% | -6.43% |
| 2020 | -11.06% | 5.02% | 16.17% | 16.08% | -16.89% | 5.28% | 43.31% | -10.64% | -1.83% | -0.93% | 2.35% | 13.65% | 59.67% |
| 2019 | 3.70% | 16.77% | 1.80% | -4.94% | -14.47% | 2.60% | 0.64% | -0.64% | -9.66% | 5.46% | -0.90% | 6.82% | 3.71% |
| 2018 | -9.37% | 0.22% | 5.82% | -10.89% | 17.00% | -14.33% | -11.96% | -15.35% | -2.68% | -23.83% | 14.89% | -14.81% | -53.58% |
| 2017 | 9.05% | 3.09% | 7.12% | 2.62% | 1.70% | 1.34% | -4.11% | 2.80% | 10.20% | 20.22% | -3.21% | 33.02% | 114.17% |
| 2016 | -17.60% | -2.80% | 18.76% | -1.40% | -4.27% | -4.56% | 0.64% | 18.30% | 7.11% | -1.04% | 2.31% | -2.66% | 7.67% |
| 2015 | 0.54% | -8.02% | 0.19% | 14.31% | 13.03% | -13.92% | -20.00% | 0.02% | 7.06% | 4.12% | -0.59% | -10.36% | -18.09% |
| 2014 | 2.14% | 15.93% | -2.35% | -2.96% | 9.92% | 0.35% | -10.90% | -0.79% | -0.60% | 11.38% | -0.36% | 0.36% | 21.12% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of 2196.HK is 62, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Shanghai Fosun Pharmaceutical Group Co Ltd (2196.HK) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Loading data...
Dividends
Dividend History
Shanghai Fosun Pharmaceutical Group Co Ltd provided a 2.18% dividend yield over the last twelve months, with an annual payout of HK$0.30 per share.
| Period | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend | HK$0.30 | HK$0.30 | HK$0.46 | HK$0.66 | HK$0.52 | HK$0.43 | HK$0.36 | HK$0.46 | HK$0.40 | HK$0.38 | HK$0.36 | HK$0.34 |
Dividend yield | 2.18% | 2.13% | 2.71% | 2.64% | 1.51% | 1.16% | 1.53% | 2.00% | 0.80% | 1.59% | 1.58% | 1.22% |
Monthly Dividends
The table displays the monthly dividend distributions for Shanghai Fosun Pharmaceutical Group Co Ltd. The dividends shown in the table have been adjusted to account for any splits that may have occurred.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | |||||||
| 2024 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.30 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.30 |
| 2023 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.46 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.46 |
| 2022 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.66 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.66 |
| 2021 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.52 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.52 |
| 2020 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.43 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.43 |
| 2019 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.36 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.36 |
| 2018 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.46 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.46 |
| 2017 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.40 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.40 |
| 2016 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.38 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.38 |
| 2015 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.36 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.36 |
| 2014 | HK$0.34 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.34 |
Dividend Yield & Payout
Dividend Yield
Shanghai Fosun Pharmaceutical Group Co Ltd has a dividend yield of 2.18%, which is quite average when compared to the overall market.
Payout Ratio
Shanghai Fosun Pharmaceutical Group Co Ltd has a payout ratio of 36.14%, which is quite average when compared to the overall market. This suggests that Shanghai Fosun Pharmaceutical Group Co Ltd strikes a balance between reinvesting profits for growth and paying dividends to shareholders.
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading data...
Worst Drawdowns
The table below displays the maximum drawdowns of the Shanghai Fosun Pharmaceutical Group Co Ltd. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Shanghai Fosun Pharmaceutical Group Co Ltd was 84.57%, occurring on Apr 16, 2024. The portfolio has not yet recovered.
The current Shanghai Fosun Pharmaceutical Group Co Ltd drawdown is 80.88%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -84.57% | Aug 5, 2021 | 663 | Apr 16, 2024 | — | — | — |
| -62.8% | Mar 21, 2018 | 489 | Mar 16, 2020 | 278 | May 3, 2021 | 767 |
| -50.19% | Jun 1, 2015 | 162 | Jan 21, 2016 | 338 | Jun 8, 2017 | 500 |
| -21.94% | Jan 15, 2018 | 20 | Feb 9, 2018 | 25 | Mar 20, 2018 | 45 |
| -19.74% | Mar 12, 2014 | 26 | Apr 16, 2014 | 247 | Apr 21, 2015 | 273 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading data...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Shanghai Fosun Pharmaceutical Group Co Ltd over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of Shanghai Fosun Pharmaceutical Group Co Ltd, comparing actual results with analytics estimates. The company has exceeded analyst expectations for EPS in the past quarter, achieving a 13.7% positive surprise.
Valuation
The Valuation section provides an overview of how Shanghai Fosun Pharmaceutical Group Co Ltd is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for 2196.HK, comparing it with other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, 2196.HK has a P/E ratio of 11.7. This P/E ratio is in line with the industry average, suggesting the stock may be fairly valued relative to its earnings.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for 2196.HK compared to other companies in the Drug Manufacturers - Specialty & Generic industry. 2196.HK currently has a PEG ratio of 1.0. This PEG ratio is low compared to industry peers, which could indicate the stock is undervalued relative to its expected growth.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for 2196.HK relative to other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, 2196.HK has a P/S ratio of 1.5. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for 2196.HK in comparison with other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, 2196.HK has a P/B value of 0.7. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |